Anti-Inflammatory and Utero-Relaxant Effects in Human Myometrium of New Generation Phosphodiesterase 4 Inhibitors

Biology of Reproduction

Volumn 70, Issue 2, 2004, Pages 458-464

  Oger, Stéphanie ^a   Méhats, Céline ^a   Barnette, Mary S ^b   Ferré, Françoise ^a   Cabrol, Dominique ^c   Leroy, Marie Josèphe ^a  

^a INSERM   (France)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Universite René Descartes ^*  (France)

Author keywords

Cytokines; Parturition; Phosphodiesterases; Pregnancy; Uterus

Indexed keywords

4 (2 AMINOPYRIMIDIN 5 YLETHYNYL) 4 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL]CYCLOHEXYL 1 AMINE; 8 BROMO CYCLIC AMP; CILOMILAST; COMPOUND A; CYCLIC AMP; FORSKOLIN; LIPOPOLYSACCHARIDE; PHOSPHODIESTERASE 4A; PHOSPHODIESTERASE 4B; PHOSPHODIESTERASE 4D; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHILDBIRTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SELECTIVITY; ENZYME ACTIVITY; EXPLANT; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; METRITIS; MYOMETRIUM; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; SMOOTH MUSCLE CONTRACTION; TISSUE CULTURE; UTERORELAXANT ACTIVITY; UTERUS CONTRACTION; UTERUS RELAXATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; CARBOXYLIC ACIDS; CYCLIC AMP; ETHERS; FEMALE; HUMANS; HYDROCARBONS, FLUORINATED; LIPOPOLYSACCHARIDES; MYOMETRIUM; NITRILES; PHOSPHODIESTERASE INHIBITORS; PREGNANCY; ROLIPRAM; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CONTRACTION;

EID: 0742288911     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod.103.023051     Document Type: Article

References (43)

1. Goncalves LF, Chaiworapongsa T, Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev 2002; 8:3-13.
2. Pollard JK, Mitchell MD. Intrauterine infection and the effects of inflammatory mediators on prostaglandin production by myometrial cells from pregnant women. Am J Obstet Gynecol 1996; 174:682-686.
3. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000; 342:1500-1507.
4. Bourne HR, Lichtenstein LM, Melmon KL, Henney CS, Weinstein Y, Shearer GM. Modulation of inflammation and immunity by cyclic AMP. Science 1974; 184:19-28.
5. Teixeira MM, Gristwood RW, Cooper N, Hellewell PG. Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? Trends Pharmacol Sci 1997; 18:164-171.
6. Kast RE. Tumor necrosis factor has positive and negative self-regulatory feedback cycles centered around cAMP. Int J Immunopharmacol 2000; 22:1001-1006.
7. Riemer RK, Heymann MA. Regulation of uterine smooth muscle function during gestation. Pediatr Res 1998; 44:615-627.
8. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003; 370:1-18.
9. Leroy MJ, Lugnier C, Merezak J, Tanguy G, Olivier S, Le Bec A, Ferre F. Isolation and characterization of the rolipram-sensitive cyclic AMP-specific phosphodiesterase (type IV PDE) in human term myometrium. Cell Signal 1994; 6:405-412.
10. Burnouf C, Pruniaux MP. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 2002; 8:1255-1296.
11. Barnette MS. Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 1999; 53:193-229.
12. Muise ES, Chute IC, Claveau D, Masson P, Boulet L, Tkalec L, Pon DJ, Girard Y, Frenette R, Mancini JA. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors. Biochem Pharmacol 2002; 63:1527-1535.
13. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-alpha and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995; 155:4909-4916.
14. Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, Taylor JD, Furdon PJ. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1995; 272:1313-1320.
15. Timmer W, Leclerc V, Birraux G, Neuhauser M, Hatzelmann A, Bethke T, Wurst W. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol 2002; 42:297-303.
16. Leroy MJ, Cedrin I, Breuiller M, Giovagrandi Y, Ferre F. Correlation between selective inhibition of the cyclic nucleotide phosphodiesterases and the contractile activity in human pregnant myometrium near term. Biochem Pharmacol 1989; 38:9-15.
17. Bardou M, Cortijo J, Loustalot C, Taylor S, Perales-Marin A, Mercier FJ, Dumas M, Deneux-Tharaux C, Frydman R, Morcillo EJ, Advenier C. Pharmacological and biochemical study on the effects of selective phosphodiesterase inhibitors on human term myometrium. Naunyn Schmiedebergs Arch Pharmacol 1999; 360:457-463.
18. Mehats C, Tanguy G, Dallot E, Robert B, Rebourcet R, Ferre F, Leroy MJ. Selective up-regulation of phosphodiesterase-4 cyclic adenosine 3′,5′-monophosphate (cAMP)-specific phosphodiesterase variants by elevated cAMP content in human myometrial cells in culture. Endocrinology 1999; 140:3228-3237.
19. Mehats C, Tanguy G, Paris B, Robert B, Pernin N, Ferre F, Leroy MJ. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the uterorelaxant effect of PDE4-selective inhibitors. J Pharmacol Exp Ther 2000; 292:817-823.
20. Oger S, Mehats C, Dallot E, Ferre F, Leroy MJ. Interleukin-1beta induces phosphodiesterase 4B2 expression in human myometrial cells through a prostaglandin E(2)- and cyclic adenosine 3′,5′ -monophosphate-dependent pathway. J Clin Endocrinol Metab 2002; 87:5524-5531.
21. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol 1999; 128:1393-1398.
22. Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2001; 10:1361-1379.
23. Kincaid RL, Manganiello VC. Assay of cyclic nucleotide phosphodiesterase using radiolabeled and fluorescent substrates. Methods Enzymol 1988; 159:457-470.
24. Leroy MJ, Pichard AL, Cabrol D, Ferre F. Cyclic 3′:5′ -nucleotide phosphodiesterase in human myometrium at the end of pregnancy: partial purification and characterization of the different soluble isoenzymes. Gynecol Obstet Invest 1985; 20:27-36.
25. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
26. Leroy MJ, Blot P, Ferre F. Characterization by DEAE-cellulose chromatography of a single molecular form of cyclic nucleotide phosphodiesterase in the myometrium of nonpregnant women. Gynecol Obstet Invest 1987; 24:190-199.
27. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001; 297:267-279.
28. Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ. SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J Pharmacol Exp Ther 1998; 284:420-426.
29. Fidel PL Jr, Romero R, Wolf N, Cutright J, Ramirez M, Araneda H, Cotton DB. Systemic and local cytokine profiles in endotoxin-induced preterm parturition in mice. Am J Obstet Gynecol 1994; 170:1467-1475.
30. Kaga N, Katsuki Y, Obata M, Shibutani Y. Repeated administration of low-dose lipopolysaccharide induces preterm delivery in mice: a model for human preterm parturition and for assessment of the therapeutic ability of drugs against preterm delivery. Am J Obstet Gynecol 1996; 174:754-759.
31. Cox SM, MacDonald PC, Casey ML. Assay of bacterial endotoxin (lipopolysaccharide) in human amniotic fluid: potential usefulness in diagnosis and management of preterm labor. Am J Obstet Gynecol 1988; 159:99-106.
32. Sehringer B, Schafer WR, Wetzka B, Deppert WR, Brunner-Spahr R, Benedek E, Zahradnik HP. Formation of proinflammatory cytokines in human term myometrium is stimulated by lipopolysaccharide but not by corticotropin-releasing hormone. J Clin Endocrinol Metab 2000; 85:4859-4865.
33. Souness JE, Griffin M, Maslen C, Ebsworth K, Scott LC, Pollock K, Palfreyman MN, Karlsson JA. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br J Pharmacol 1996; 118:649-658.
34. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A 2002; 99:7628-7633.
35. Eigler A, Siegmund B, Emmerich U, Baumann KH, Hartmann G, Endres S. Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production. J Leukoc Biol 1998; 63:101-107.
36. Newell CL, Deisseroth AB, Lopez-Berestein G. Interaction of nuclear proteins with an AP-1/CRE-like promoter sequence in the human TNF-alpha gene. J Leukoc Biol 1994; 56:27-35.
37. Navarro J, Punzon C, Jimenez JL, Fernandez-Cruz E, Pizarro A, Fresno M, Munoz-Fernandez MA. Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol 1998; 72:4712-4720.
38. Jimenez JL, Punzon C, Navarro J, Munoz-Fernandez MA, Fresno M. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther 2001; 299:753-759.
39. Thomson AJ, Telfer JF, Young A, Campbell S, Stewart CJ, Cameron IT, Greer IA, Norman JE. Leukocytes infiltrate the myometrium during human parturition: further evidence that labour is an inflammatory process. Hum Reprod 1999; 14:229-236.
40. Ma D, Wu P, Egan RW, Billah MM, Wang P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol Pharmacol 1999; 55:50-57.
41. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol 1999; 56:170-174.
42. Norwitz ER, Robinson JN. A systematic approach to the management of preterm labor. Semin Perinatol 2001; 25:223-235.
43. Trifilieff A, Wyss D, Walker C, Mazzoni L, Hersperger R. Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo [1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti-inflammatory activities. J Pharmacol Exp Ther 2002; 301:241-248.